{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T10:16:24Z","timestamp":1767694584968,"version":"3.48.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,7,13]],"date-time":"2025-07-13T00:00:00Z","timestamp":1752364800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"UTMB Center of Excellence for Professional Advancement and Research","award":["D34HP49234-01-00"],"award-info":[{"award-number":["D34HP49234-01-00"]}]},{"DOI":"10.13039\/100000102","name":"Health Resources and Services Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000102","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Sickle cell disease (SCD) is an autosomal recessive disorder characterized by abnormal hemoglobin (Hb), vaso-occlusive crises, and hemolytic anemia. Hydroxyurea has been proven effective in managing SCD but is associated with nonhealing skin ulcers. Additionally, its effects on wound healing in burn patients remain unclear. This study investigates the role of hydroxyurea in mortality, wound infection, wound disruption, and sepsis among SCD patients with burn injuries. Using the TriNetX database, cohorts were identified based on ICD-10 codes for adult patients aged 18\u00a0years or older diagnosed with SCD, previous burn injury, and hydroxyurea use. Propensity score matching was performed for demographics (age, sex, race, ethnicity), comorbidities that affect wound healing, and clinical variables (burn severity and SCD severity). Mortality, wound infection, wound disruption, and sepsis were assessed at 30\u00a0days, 3 months, and 6 months postburn injury. Statistical methods such as chi-square analysis and risk ratio were used, with a statistical significance at P &amp;lt; .05. Hydroxyurea cohort had significantly higher risk for wound healing outcomes such as wound disruption, wound infection, and recurrent sepsis at each time outcome. However, hydroxyurea cohort had a significantly lower risk of mortality compared to the control group at each time outcome. This study highlights the need to consider hydroxyurea\u2019s impact on wound healing when developing treatments for SCD patients with burn injury. Further research is needed to investigate its mechanism in wound healing processes and develop safer treatment alternatives.<\/jats:p>","DOI":"10.1093\/jbcr\/iraf137","type":"journal-article","created":{"date-parts":[[2025,7,13]],"date-time":"2025-07-13T03:46:17Z","timestamp":1752378377000},"page":"207-213","source":"Crossref","is-referenced-by-count":0,"title":["Hydroxyurea Therapy and Burn Wound Healing in Sickle Cell Disease: A TriNetX Database Study"],"prefix":"10.1093","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-4785-2011","authenticated-orcid":false,"given":"Joshua E","family":"Lewis","sequence":"first","affiliation":[{"name":"John Sealy School of Medicine, University of Texas Medical Branch , Galveston, TX 77555-1317 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Austin","family":"Biscotti","sequence":"additional","affiliation":[{"name":"John Sealy School of Medicine, University of Texas Medical Branch , Galveston, TX 77555-1317 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jarrell","family":"Patterson","sequence":"additional","affiliation":[{"name":"Brody School of Medicine , Greenville, NC 27834 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryce","family":"Gantt","sequence":"additional","affiliation":[{"name":"Howard University College of Medicine , Washington, DC 20059 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelsey M","family":"Green","sequence":"additional","affiliation":[{"name":"Howard University College of Medicine , Washington, DC 20059 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Areeba","family":"Navroz","sequence":"additional","affiliation":[{"name":"John Sealy School of Medicine, University of Texas Medical Branch , Galveston, TX 77555-1317 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernst J","family":"Nicanord","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, University of Texas Medical Branch John Sealy Hospital , Galveston, TX 77555-1123 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,7,13]]},"reference":[{"volume-title":"Addressing Sickle Cell Disease: A Strategic Plan and Blueprint for Action","year":"2020","author":"National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Population Health and Public Health Practice; Committee on Addressing Sickle Cell Disease: A Strategic Plan and Blueprint for Action","key":"2026010605120889100_ref1"},{"key":"2026010605120889100_ref2","doi-asserted-by":"publisher","first-page":"e1915374","DOI":"10.1001\/jamanetworkopen.2019.15374","article-title":"Estimated life expectancy and income of patients with sickle cell disease compared with those without sickle cell disease","volume":"2","author":"Lubeck","year":"2019","journal-title":"JAMA Netw Open"},{"volume-title":"StatPearls","year":"2023","author":"Warby","key":"2026010605120889100_ref3"},{"key":"2026010605120889100_ref4","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1177\/0022034509359125","article-title":"Factors affecting wound healing","volume":"89","author":"Guo","year":"2010","journal-title":"J Dent Res"},{"key":"2026010605120889100_ref5","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1503\/cmaj.081042","article-title":"Hydroxyurea-induced ulcers on the leg","volume":"180","author":"Dissemond","year":"2009","journal-title":"CMAJ Can Med Assoc J"},{"key":"2026010605120889100_ref6","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1001\/archderm.143.10.1310","article-title":"Hydroxyurea-induced leg ulcers treated with a protease-modulating matrix","volume":"143","author":"Romanelli","year":"2007","journal-title":"Arch Dermatol"},{"key":"2026010605120889100_ref7","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1001\/archderm.135.7.818","article-title":"Leg ulcers and hydroxyurea: forty-one cases","volume":"135","author":"Sirieix","year":"1999","journal-title":"Arch Dermatol"},{"key":"2026010605120889100_ref8","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1097\/MOH.0b013e32834521dd","article-title":"Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain?","volume":"18","author":"McGann","year":"2011","journal-title":"Curr Opin Hematol"},{"key":"2026010605120889100_ref9","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.burns.2008.06.002","article-title":"Burn prevention mechanisms and outcomes: pitfalls, failures and successes","volume":"35","author":"Atiyeh","year":"2009","journal-title":"Burns J Int Soc Burn Inj"},{"key":"2026010605120889100_ref10","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.59619","article-title":"Exploring the demographic and social correlates of burn injuries: a comprehensive study from a regional burn center in Pakistan","author":"Ul","year":"2024","journal-title":"Cureus"},{"key":"2026010605120889100_ref11","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1111\/wrr.12432","article-title":"Current concepts related to hypertrophic scarring in burn injuries","volume":"24","author":"Chiang","year":"2016","journal-title":"Wound Repair Regen Off Publ Wound Heal Soc Eur Tissue Repair Soc"},{"key":"2026010605120889100_ref12","doi-asserted-by":"publisher","first-page":"ooad035","DOI":"10.1093\/jamiaopen\/ooad035","article-title":"A global federated real-world data and analytics platform for research","volume":"6","author":"Palchuk","year":"2023","journal-title":"JAMIA Open"},{"key":"2026010605120889100_ref13","doi-asserted-by":"publisher","first-page":"6404","DOI":"10.3390\/jcm13216404","article-title":"The current role of hydroxyurea in the treatment of sickle cell Anemia","volume":"13","author":"L\u00f3pez Rubio","year":"2024","journal-title":"J Clin Med"},{"key":"2026010605120889100_ref14","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1002\/ajh.26120","article-title":"Hydroyxurea improves cerebral oxygen saturation in children with sickle cell anemia","volume":"96","author":"Karkoska","year":"2021","journal-title":"Am J Hematol"},{"key":"2026010605120889100_ref15","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1517\/14740338.2015.1088827","article-title":"Hydroxyurea therapy for sickle cell anemia","volume":"14","author":"McGann","year":"2015","journal-title":"Expert Opin Drug Saf"},{"volume-title":"Hydroxyurea \u2013 an overview","key":"2026010605120889100_ref16"},{"key":"2026010605120889100_ref17","first-page":"101","article-title":"Hydroxyurea: overview of clinical data and antiretroviral and immunomodulatory effects","volume":"4","author":"Lori","year":"1999","journal-title":"Antivir Ther"},{"key":"2026010605120889100_ref18","doi-asserted-by":"publisher","first-page":"102673","DOI":"10.1016\/j.isci.2021.102673","article-title":"Mitochondria-targeted hydroxyurea inhibits OXPHOS and induces antiproliferative and immunomodulatory effects","volume":"24","author":"Cheng","year":"2021","journal-title":"iScience"},{"key":"2026010605120889100_ref19","doi-asserted-by":"publisher","first-page":"14829","DOI":"10.1038\/s41598-019-51339-x","article-title":"Hydroxyurea alters circulating monocyte subsets and dampens its inflammatory potential in sickle cell anemia patients","volume":"9","author":"Guarda","year":"2019","journal-title":"Sci Rep"},{"key":"2026010605120889100_ref20","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1182\/blood.v99.7.2297","article-title":"Hydroxyurea corrects the dysregulated L-selectin expression and increased H(2)O(2) production of polymorphonuclear neutrophils from patients with sickle cell anemia","volume":"99","author":"Benkerrou","year":"2002","journal-title":"Blood."},{"key":"2026010605120889100_ref21","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/0883-9441(89)90003-8","article-title":"Neutrophil depletion with hydroxyurea ameliorates lung reperfusion injury","volume":"4","author":"Bishop","year":"1989","journal-title":"J Crit Care"},{"key":"2026010605120889100_ref22","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/j.1365-2249.2007.03412.x","article-title":"Hydroxyurea exerts an anti-proliferative effect on T cells but has no direct impact on cellular activation","volume":"149","author":"Benito","year":"2007","journal-title":"Clin Exp Immunol"},{"volume-title":"Hydroxyurea: MedlinePlus drug information","key":"2026010605120889100_ref23"},{"key":"2026010605120889100_ref24","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1097\/00002030-200501280-00005","article-title":"Hydroxyurea exerts a cytostatic but not immunosuppressive effect on T lymphocytes","volume":"19","author":"Lova","year":"2005","journal-title":"AIDS Lond Engl"},{"volume-title":"Immunosuppressive agents","key":"2026010605120889100_ref25"},{"key":"2026010605120889100_ref26","doi-asserted-by":"publisher","first-page":"1759720X20947296","DOI":"10.1177\/1759720X20947296","article-title":"Oral disease-modifying antirheumatic drugs and immunosuppressants with antiviral potential, including SARS-CoV-2 infection: a review","volume":"12","author":"Tsai","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"volume-title":"Droxia Siklos (hydroxyurea) dosing, indications, interactions, adverse effects, and more","key":"2026010605120889100_ref27"},{"key":"2026010605120889100_ref28","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s41038-019-0148-1","article-title":"Advances in surgical applications of growth factors for wound healing","volume":"7","author":"Yamakawa","year":"2019","journal-title":"Burns Trauma"},{"key":"2026010605120889100_ref29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-024-01852-x","article-title":"Harnessing the potential of hydrogels for advanced therapeutic applications: current achievements and future directions","volume":"9","author":"Lu","year":"2024","journal-title":"Signal Transduct Target Ther"}],"container-title":["Journal of Burn Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbcr\/advance-article-pdf\/doi\/10.1093\/jbcr\/iraf137\/63735908\/iraf137.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbcr\/article-pdf\/47\/1\/207\/63735908\/iraf137.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbcr\/article-pdf\/47\/1\/207\/63735908\/iraf137.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T10:12:14Z","timestamp":1767694334000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbcr\/article\/47\/1\/207\/8198093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,13]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,7,13]]},"published-print":{"date-parts":[[2026,1,6]]}},"URL":"https:\/\/doi.org\/10.1093\/jbcr\/iraf137","relation":{},"ISSN":["1559-047X","1559-0488"],"issn-type":[{"type":"print","value":"1559-047X"},{"type":"electronic","value":"1559-0488"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,7,13]]}}}